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Amphiphilic bile acids linked through an oligoethylene glycol to a biotin moiety were synthesized and
shown to create micellar structures in aqueous environment, interact with avidin and be efﬁciently
incorporated into hepatocyte cells, suggesting their potential as a drug delivery system against liver
diseases.
Introduction
The success of a drug therapy derives from the achievement of
effective drug concentrations at the target site. However, this goal
is often complicated by several factors, including those related to
physical properties of the active ingredient, such as water solu-
bility, membrane permeability and metabolic stability. Because of
the difﬁculties associated with drug therapy, the design of new
delivery systems remains a great challenge in medicinal chemistry.
Vehicles include nanoparticles,1 microcapsules,2 liposomes,3 and
micelles.4 The decoration of nanoparticle surfaces with molecules
capable of targeting a speciﬁc cell type or tissue (e.g., antibodies,
saccharides or peptides), is essential to develop an efﬁcient delivery
system.5,6 In addition, such nanosystems should be non-toxic,
biocompatible, possibly easy to synthesize, stable and possessing
long half-life in biological ﬂuids.
Among the human organs, the liver plays a primary role in
the protection of organisms by assault of xenobiotics and in the
synthesis of blood plasma components. For these reasons hepatic
diseases, such as hepatitis, cirrhosis and liver cancers, represent a
serious problem for human health.7–9 Acrucial step for a successful
treatment of hepatic diseases is the need to reduce side effects,
which might be achieved by using nanostructures containing
molecules able to selectively interact with speciﬁc hepatocyte
membrane receptors.
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Within this effort, we describe here the synthesis and the
structural characterization of biotinylated bile acid amphiphiles
(BBAA, 1–4, Fig. 1) containing, in the lipophilic region, different
bile acids, namely cholic acid 1 (CA), deoxycholic acid 2 (DCA),
ursodeoxycholic acid 3 (UDCA) and lithocholic acid 4 (LA). Bile
acids are recognized by speciﬁc transport systems on hepato-
cyte membranes10,11 and this property has made them excellent
molecules to be included in liver drug targeting systems.12,13
Moreover, the presence of bile acids, such as UDCA, may
itself be valuable, because UDCA is an hepatoprotector that
stabilizes the liver membrane in cholestatic injury.14 Biotinylated
lithocholic acids have been demonstrated to inhibit mammalian
DNA polymerases.15 In this work, biotin and bile acids were
linked by an oligoethyleneglycol (OEG-8) chain selected for
its biocompatibility and because OEG-8 was demonstrated to
Fig. 1 Synthesized BBAA and a schematic representation of the orienta-
tion of bile acid and biotin in micelles.
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 2899–2905 | 2899
Pu
bl
ish
ed
 o
n 
03
 M
ar
ch
 2
01
1.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
20
/0
7/
20
15
 1
1:
04
:0
6.
 
View Article Online / Journal Homepage / Table of Contents for this issue
Scheme 1 Synthesis of biotinylated bile acid amphiphiles.
positively affect cell permeability and to increase the nanoparticle
concentration in target tissues.16–18
Results and discussion
BBAA 1–4 were synthesized by two sequential esteriﬁcation cou-
plings with OEG-8 and biotin, respectively (Scheme 1). Because
of the reactivity of the hydroxyl groups of bile acids, a preliminary
OH-protection with dihydropyran was needed (compounds 5–8,
Scheme 1).19
These molecules were assessed in water as to their tendency
to form micellar aggregates spontaneously. Table 1 summarizes
the fundamental micelle properties for 1–4. The order in water
solubility was 1 > 2 ≥ 3 > 4, which inversely reﬂects the ability
of forming aggregates as determined by the respective CMC
values.
The ability of BBAA 1–4 to self-associate forming micellar
aggregates in aqueous phase was determined by ﬂuorescence
analysis using pyrene as a probe.12,20–24 In Fig. S1 (ESI†), the
pyrene excitation spectra at various concentrations of 1–4 are
shown.
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Table 1 Micelles characterization
1 2 3 4
Water solubility (mg mL-1) 2.0 1.0 1.0 0.5
CMC (mol L-1)a n.m.f.c 1.2 ¥
10-3
7.5 ¥ 10-5 1.2 ¥ 10-5
Average d (nm)b n.m.f.c 122 ± 7 140 ± 11 82 ± 5
a Calculated by pyrene excitation spectra. b Diameter determined by
dynamic light scattering. c No micelle formation.
In the pyrene excitation spectra of 1, no shift of pyrene spectra
was observed, suggesting that the CA-(OEG-8)-biotin conjugate
is not able to create micelles in water. In contrast, the spectra of
2–4 show a gradual shift of pyrene from 333.5 to 337.5 nm for
2, from 334.0 to 337.0 nm for 3, and from 334.0 to 338.0 nm
for 4, typical of the formation of micelles in water. The shift
of pyrene spectra was recorded in solutions at concentrations
higher than 10-2 g L-1. By plotting the values of I 337.5/I 333.5 for 2,
I 337/I 334 for 3 and I 338/I 334 for 4 vs. the logarithm of concentration,
it was possible to obtain a distribution curve of the respective
micelle formation (Fig. 2), which was used to determine the
CMC values of 2–4 (Table 1). Dynamic light scattering (DLS)
was used to conﬁrm the presence of micelles or larger aggregates
and to determine the relevant hydrodynamic sizes (Fig. S2, ESI†),
which were in the same order of other recent observations.25 In
particular, previous evidence supports the idea that bile acids
derivatives tend to form multimicellar aggregates in concentrated
solutions.26 Micelles from BBAA showed long-term stability in
water. The DLS distributions of 2–4 dispersions after 1 month are
reported in the ESI† (Fig. S3). A size increment within 20% and
the maintenance of a narrow size distribution provided evidence
on the BBAA aggregate stability.
An insight into the molecular features of 1–4 evidenced that
aggregate formation could be associated with the number of
hydroxyl functionalities. In fact, while compound 1 containing
3 OH groups was unable to create assemblies, compound 4, which
contains only one free hydroxyl, exhibited a strong propensity
to form micelles in aqueous media, as conﬁrmed by the low
experimental CMC. BBAA 2 and 3were also able to self-assemble
into organized structures, but these structures were remarkably
larger than those formed from 4, as these compounds hold 2
hydroxyl groups, giving an intermediate hydrophilic character
between 1 and 4. ComparingCMCvalues of 2 and 3 suggested that
the aggregate formation should bemore favored by the presence of
hydroxyl group at 7 rather than at 12 position in the cyclopentane
perihydrophenantrenic ring.
Since biotin (bt) was present in all BBAA, we have tested the
ability of these molecules to bind avidin (Av). Av–bt interaction,
indeed, could be very useful in pretargeting approaches to cancer
Fig. 2 Plot of I 337.5/I 333.5 (2), I 337/I 334 (3) and I 338/I 334 (4) vs. log C for 2, 3 and 4 at 25 ◦C.
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and inﬂammatory diseases.27 The afﬁnity of 1–4 towards Av was
assessed using a spectrophotometric assay.28 The Green method
is based on monitoring 4-hydroxyazobenzene-2-carboxylic acid
(HABA), which binds to Av and can be used as an indicator of
binding sites occupied by bt.29 Fig. 3a shows the concentration
and the percentage of saturated Av binding sites.
Fig. 3 A) Percentage of Av binding sites occupied by bt and BBAA 1–4.
B) Progress of binding between Av-bt and Av-BBAA 1–3 vs. time.
BBAA 1–3 exhibited an afﬁnity forAv comparable to that of free
bt used as control. BBAA 4, however, provided an apparent lower
afﬁnity because it was not possible to prepare the optimal solution
(2 mM) necessary for the assay, as the concentration required was
higher than the maximal solubility of this compound (1 mM).
Hence, although the quantitative data for 4 were considered
unreliable, we could conclude that, because of the similarity with
the other molecules, 4 was also able to bind Av. Fig. 3b shows
the time dependence of formation of the Av-bt complex for 1–
3. Compound 1 could saturate Av within 1 min, similar to free
bt (0.5 min), while 2 and 3 were 5 times slower. The remarkable
difference in the rate of formation of a stable complex with Av
might be explained in terms of the different molecular state in
solution, which would result in lower rates when amphiphiles are
assembled into micelles. We can assume that the bt of amphiphilic
compounds which form micelles at ﬁrst should be not able to
interact with Av beacause they are engaged directly in micelle
formation. Only after the micelles have been completely formed
and bt is in contact with water, does it become able to bind Av.
This assumption was conﬁrmed by the behaviour of compond 1,
which, being unable to form micelles, was found to bind Av in a
time on the same order of free bt. In order to evaluate whether
the complex formation would occur involving entire micelles
or whether the binding with Av would induce the aggregate
disruption, a spectroﬂuorimetric assaywas undertaken.A solution
of pyrene was added in parallel to two samples, each with a
concentration of 1.0 mg mL-1 for compounds 2 and 3 and of 0.5
mg mL-1 for 4, higher than CMC.21 To the ﬁrst sample was added
a solution of Av (0.1 mg mL-1) in order to reach a 1 : 20 Av/bt
ratio whereas to the second was added Av to reach a 1 : 100 Av/bt
ratio.
In Fig. 4, the band of pyrene resulted in different peaks
depending on Av concentration. In particular, 1) the ﬁrst sample
(band 3, red, 1 : 20 Av/bt ratio) was detected as a peak at 333.5
nm for 2, 333.8 nm for 3 and 334.7 nm for 4, typical of free pyrene
in solution (band 1, black), suggesting that high concentrations of
Av may lead to micelle disruption; 2) the second sample (band 4,
green, 1 : 100 Av/bt ratio) displays a peak at 336.6 nm for 2, 336.0
nm for 3 and 337.0 nm for 4. In this case, the pyrene shift proved
to be similar to the one corresponding to the formation of micelles
(band 2, blue) suggesting that at this concentration Av is able to
bind with amphiphilic bile acids without micelle distruption. DLS
of the above samples 1 and 2 conﬁrmed the spectroﬂuorimetric
data. For example, in the ﬁrst sample of BBAA 4, corresponding
to band 3 in Fig. 4, unorganized small aggregates were observed as
a consequence of micelle disruption due to the excess of Av used in
the experiment. DLS of the second sample revealed the presence
of larger aggregates (800 nm), which could be interpreted in terms
of multimicelle agglomeration induced by tetrameric Av bridging.
Finally, to preliminarily assess whether micelles derived from
our BBAA could be uptaken by hepatocyte cells, a murine
hepatic cell line was incubated with the different compounds
using a concentration high enough to allow the formation of
stable micelles. As a proof of concept, for this experiment we
selected BBAA 4, derived from lithocholic acid. As shown in
Fig. 5, incubation with 4 resulted in an efﬁcient uptake of BBAA
Fig. 4 Pyrene excitation spectra of compounds 2–4 in presence of Av: band 1 (black) pyrene shift without micelles formation; band 2 (blue) pyrene shift
with micelles formation; band 3 (red) pyrene shift with 1 : 20 Av/bt ratio; band 4 (green) pyrene shift with 1 : 100 Av/bt ratio.
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Fig. 5 Bile acid amphiphilic molecules uptake in Hepatic cells. A
representative panel of (A)Hepa 1–6 cells under basal conditions, (B) upon
incubation with biotin only, and (C) incubated with a bile acid amphiphilic
molecule compounds. A magniﬁcation of the squared box is presented in
D to F, respectively. Nuclei were stained with DAPI (blue signal) and bt
was revealed following FITC-streptavidin staining (green signal).
compared to cells under basal conditions (free biotin was used as
control). Indeed, FITC-labeled SAv ﬂuorescence was detected in
treated cells.
Conclusions
In summary, we have described a series of amphiphilic molecules
(1–4), obtained from biocompatible scaffolds, designed for liver
drug targeting, characterized by a biotin moiety linked through an
OEG-8 to four different bile acid sources (CA, DCA,UDCA, LA,
respectively). Out of them, 2–4 proved to make micellar structures
efﬁciently in aqueous solution.Moreover, all compoundswere able
to interact with avidin and, in particular, 2–4 were demonstrated
to bind with avidin in the form of micelles. Preliminary in vitro
data showed that such micelles could be efﬁciently incorporated
into hepatic cells and still be able to be targeted by labeled
streptavidin. Because of their characteristics of biocompatibility,
water solubility and ease of preparation, these synthetic nanoscale
vectors can be excellent starting materials for the development
of new delivery vehicles for the diagnosis and treatment of liver
diseases.
Experimental
Materials and apparatus
Chemicals and solvents were purchased from Iris Biotech (Mark-
tredwitz, Germany), Sigma–Aldrich (Schnelldorf, Germany) and
Alfa Aesar (Karlsruhe, Germany) and used without further puriﬁ-
cations. Avidin was purchased from Apollo Scientiﬁc (Stockport,
England). Thin layer chromatography (TLC) was performed
using Al-backed sheets coated with silica gel 60F254 purchased
fromMerck (Darmstadt, Germany); spots were further evidenced
by phosphomolibdic acid (2% in ethanol). NMR spectra were
performed by using a Varian Mercury 300VX. ESI-MS was
performed by using a LTQ XL-Orbitrap mass spectrometer
(Thermo Scientiﬁc, Milan, Italy) with electrospray interface. Cap-
illary electrophoresis (CE) experiments were carried out by using
a Beckman Coulter ProteomeLab PA 800. Spectrophotometric
measurements were performed by a Perkin-Elmer LAMBDA-11.
Fluorimetric measurements were performed by a Perkin-Elmer
LS 50 B. TEM images of nanoparticles were obtained by a Zeiss
EM-109microscope (Oberkhochen, Germany) operating at 80 kV.
Dynamic Light Scattering (DLS) measurements were performed
at 90◦ with a 90 Plus Particle Size Analyzer from Brookhaven
Instrument Corporation (Holtsville, NY) working at 15 mW of a
solid-state laser (l = 661 nm). Hepatocytes images were acquired
with a Zeiss Axiovert 200 ﬂuorescence microscope.
General procedures for the synthesis of biotinylated bile acid
amphiphiles
OH protection. To a 0.1 M solution of cholic acid or deriva-
tives in dioxane, p-toluenesulfonic acid (0.1 eq.) and dihydropyran
(1 eq. per OH to be protected) were added. The reaction mixture
was stirred, at room temperature, for 30min.At the end of reaction
(TLCmonitoring), water (20 mL) was added and the solution was
concentrated in vacuo. The aqueous phasewas extractedwith ethyl
acetate (3 times) and the collected organic phases were washed
with brine (2 times), dried with anhydrous sodium sulfate and
concentrated in vacuo. The crude product was puriﬁed by ﬂash
chromatography (DCM–MeOH).
Esteriﬁcation. To a 1 M solution of protected cholic acid or
derivatives in DCM, alcohol (1 eq.), TBTU (1.2 eq.) and DMAP
(2 eq.) were added. The reaction mixture was stirred, at room
temperature, overnight. At the end of reaction (TLCmonitoring),
the reaction mixture was evaporated in vacuo and the crude
product was puriﬁed by ﬂash chromatography (DCM–MeOH).
Deprotection. To a 0.1M solution of protected BBAA in THF
a solution ofAcOH–THF–water (4 : 2 : 1, 1mL formgof protected
compound) was added. The reaction mixture was stirred, at 40
◦C, for 2 h. At the end of reaction (TLC monitoring) the mixture
was neutralized with NaHCO3, ﬁltered and evaporated in vacuo.
The crude product was puriﬁed by ﬂash chromatography (DCM–
MeOH).
CE analysis. The ﬁnal products were applied to a CE to
verify their purity: injections were performed in the hydrodynamic
mode (10 s., 0.5 psi) with a running buffer at pH = 2.5 (50 mM
phosphate). The capillary (32 cm overall length, 21 cm effective
length, 50 mm i.d.) was operated at 8 kV, while maintaining its
temperature at 25 ◦C; detection was carried out at 220 nm.
Compound 1. 25-oxo-28-(3,7,13-trihydroxy-10-methylhexade-
cahydro-1H -cyclopenta[a]phenan-thren-17 -yl)-3 ,6 ,9 ,12 ,15 ,18,
21 ,24 -octaoxanonacosyl -5 - (2 -oxohexahydro -1H - thieno[3,4-d]-
imidazol-4-yl)-pentanoate was synthesized from cholic acid (500
mg, 1.22 mmol) by OH protection, esteriﬁcation and OH depro-
tection protocols, as described above. Colourless oil (21.5 mg,
0.022 mmol).Rf 0.6 (DCM–MeOH, 90 : 10). 1H-NMR (300MHz,
CD3OD) d ppm: 4.63–4.54 (t, 1H), 4.42–4.33 (t, 1H), 4.26–
4.19 (m, 4H), 3.78–3.41 (m, 28H), 2.95–2.89 (dd, 2H), 2.80–
2.73 (t, 2H), 2.42–2.14 (m, 35H), 0.67 (s, 3H). MS (ESI)
m/z: [M+H]+ found 987.60; Calcd: 987.57. CE migration time:
3.51 min.
Compound 2. 28 - (3 ,13 -dihydroxy -10 -methylhexadecahydro-
1H-cyclopenta[a]phenanthren-17-yl)-25-oxo-3,6,9,12,15,18,21,24-
octaoxanonacosyl-5-(2-oxohexahydro-1H -thieno[3,4-d]imidazol-
4-yl)pentanoate was synthesized starting from deoxycholic acid
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 2899–2905 | 2903
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(500 mg, 1.27 mmol) by using OH protection, esteriﬁcation and
OH deprotection protocols, as described above. Colourless oil (26
mg, 0.030 mmol). Rf 0.43 (DCM–MeOH, 90 : 10). 1H-NMR (300
MHz, CD3OD) d ppm 4.56–4.49 (t, 1H), 4.37–4.26 (t, 1H), 4.24–
4.12 (m, 4H), 3.78–3.47 (m, 28H), 2.97–2.89 (dd, 2H), 2.75–2.64
(t, 2H), 2.41–2.21 (m, 6H), 1.98–0.90 (m, 35H), 0.71 (s, 3H). MS
(ESI) m/z: [M+H]+ found 971.67; Calcd: 971.58. CE migration
time: 3.60 min.
Compound 3. 28 - (3 , 7 - dihydroxy - 10 , 13 - dimethylhexadeca-
hydro-1H -cyclopenta[a]phenanthren-17-yl)-25-oxo-3,6,9,12,15,
18,21,24-octaoxanonacosyl-5-(2-oxohexahydro-1H -thieno[3,4-d]
imidazol-4-yl)pentanoate was synthesized starting from ur-
sodeoxycholic acid (500 mg, 1.27 mmol) by using OH protection,
esteriﬁcation and OH deprotection protocols, as described above.
Colourless oil (26 mg, 0.027 mmol). Rf 0.2 (DCM–MeOH, 95 : 5).
1H-NMR (300 MHz, CD3OD) ppm 4.64–4.59 (t, 1H), 4.53–4.48
(t, 1H), 4.31–4.16 (m, 4H), 3.73–3.54 (m, 28H), 2.95–2.89 (dd,
2H), 2.80–2.73 (t, 2H), 2.38–2.16 (m, 6H), 1.98–0.68 (m, 35H),
0.64 (s, 3H). MS (ESI) m/z: [M+H]+ found 971.80; Calcd: 971.58.
CE migration time: 3.62 min.
Compound 4. 28 - (3 -hydroxy -10 ,13 -dimethylhexadecahydro-
1H-cyclopenta[a]phenanthren-17-yl)-25-oxo-3,6,9,12,15,18,21,24-
octaoxanonacosyl-5-(2-oxohexahydro-1H -thieno[3,4-d]imidazol-
4-yl)-pentanoate was synthesized starting from lithocholic acid
(500 mg, 1.33 mmol) by using OH protection, esteriﬁcation and
OH deprotection protocols, as described above. Colourless oil
(30 mg, 0.03 mmol). Rf 0.55 (DCM–MeOH, 90 : 10). 1H-NMR
(300 MHz, CD3OD) ppm 4.49–4.47 (t, 1H), 4.33–4.29 (t, 1H),
4.23–4.18 (m, 4H), 3.74–3.55 (m, 28H), 2.96–2.90 (dd, 2H), 2.73–
2.69 (t, 2H), 2.49–2.18 (m, 6H), 1.91–0.94 (m, 35H), 0.69 (s, 3H).
MS (ESI)m/z: [M+H]+ found955.67;Calcd: 955.59.CEmigration
time: 3.63 min.
Micelles formation. Compounds were dissolved in THF and
HPLC water (3 mL) was added to the solution. Then, THF was
removed on a rotary evaporator al 30 ◦C for 2 h. The aqueous
solution was diluted to obtain a concentration range from 5 g L-1
to 10-4 g L-1. for the measurement of ﬂuorescence spectra, pyrene
solution in THF (1.2 ¥ 10-3 M) was diluted with HPLC-water to
give a pyrene concentration of 12 ¥ 10-7 M. THF was removed in
vacuo to obtain a 6 ¥ 10-7 M pyrene solution, which was mixed to
compound samples to obtain ﬁnal concentrations from 2.5 g L-1
to 5 ¥ 10-5 g L-1. All the samples were sonicated for 10 min and
allowed to stand for 1 day before ﬂuorescence measurement.
Fluorescence measurement. Pyrene was used as ﬂuorescence
probe to analyze the compounds in the HPLC-water. For the
measurement of pyrene excitation spectra, emission and excitation
slit width was set at 2 mm. Excitation spectra measurement was
done at lem = 393 nm and the spectra were accumulated with an
integration of 20 nm min-1.22
Avidin-Biotin bond. To 2 mL of avidin solution (1 mg pro-
tein in 0.1 M phosphate buffer at pH = 6) was added 4-
hydroxyazobenzene-2¢-carboxylic acid (HABA, 10 mM in NaOH
0.01 M, 50 mL). UV absorption was measured at 500 nm. Then
biotin or biotinylated compounds 1–4 (2 mM in 0.1 M phosphate
buffer, 50 mL) were added and absorption was measured at 500 nm
(lmax ofAvidin-HABAcomplex). Theoccupied avidin binding sites
concentration [bs] was calculated from the following relationship:
[ ]bs
A
=
D 500
34
mM
whereDA500 is the difference between absorptionswith andwith-
out biotinylated compounds and 34 is the extinction coefﬁcient of
the avidin-HABA complex at 500 nm.28
Cell culture, in vitro uptake and visualization of bile acids
amphiphilic molecules
The murine hepatoma cell line Hepa 1–6 was grown in High glu-
cose Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented
with 10% Foetal bovine serum (FBS), 2 mM L-glutamine and
100 units mL-1 of penicillin and 100 mg mL-1 of streptomycin.
Cells were grown on gelatin coated glass slides in a 24-well plate
until 70% conﬂuence, then the media was removed and cells were
incubated with bile acid amphiphilic molecule 4 at a concentration
of 0.5 mg mL-1 in FBS free medium for 6 h at 37 ◦C. Cells
were rinsed three times with ice cold PBS and ﬁxed with 4%
paraformaldehyde for 15 min at room temperature. Cells were
rinsed once more with PBS and membranes were permeabilized
with 0.2% Triton X-100 in PBS then cells were incubated with
FITC conjugated streptavidin (1 : 200 in PBS) to detect biotin
conjugated micelles and with DAPI (diamidino-2-phenylindole)
for nuclear staining.
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